Amjevita (adalimumab-atto) — FDA-Approved Biosimilar to Humira (adalimumab)

TNF-alpha Inhibitor Biosimilar · Approved 2016 · $0–$35/mo for most insured patients

🔬 What Is Amjevita?

Amjevita (adalimumab-atto) is an FDA-approved biosimilar to Humira (adalimumab). A biosimilar is a biological medication that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Amjevita (adalimumab-atto) was the first FDA-approved Humira biosimilar, approved in 2016 and commercially launched in 2023. It contains the same active ingredient (adalimumab) as Humira and is approved for all the same conditions. Amjevita is available in both citrate-free and citrate-containing formulations.

🛒 Order Amjevita — Direct from BiologicHealthPlus

Our pharmacist team will contact you within 2 hours to verify your prescription and insurance.

With Insurance

$0–$35/mo for most insured patients

Amgen SupportPlus

Uninsured / PAP

Free

Income-based assistance

Start My Order → 💬 WhatsApp 📞 Call

Amjevita Overview

Property	Details
Brand Name	Amjevita
Generic Name	adalimumab-atto
Reference Biologic	Humira (adalimumab)
Manufacturer	Amgen
Drug Class	TNF-alpha Inhibitor Biosimilar
FDA Approval	2016
Route	Subcutaneous injection
Approved Conditions	Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis, HS, Uveitis, JIA
Copay Program	Amgen SupportPlus — $0–$35/mo for most insured patients

Approved Conditions

✓Rheumatoid Arthritis✓Psoriatic Arthritis✓Ankylosing Spondylitis✓Plaque Psoriasis✓Crohn's Disease✓Ulcerative Colitis✓HS ✓Uveitis✓JIA

Amjevita vs Humira (adalimumab)

Amjevita has been demonstrated to be biosimilar to Humira (adalimumab) through comprehensive analytical, non-clinical, and clinical studies. The FDA requires that biosimilars have no clinically meaningful differences from the reference product. Patients who are stable on Humira (adalimumab) should discuss any potential switch to Amjevita with their prescriber.

Factor	Amjevita	Humira (adalimumab)
FDA Status	Biosimilar (approved 2016)	Reference biologic
Active Ingredient	adalimumab-atto	adalimumab
Mechanism	TNF-alpha Inhibitor	Same
Approved Indications	Same as Humira (adalimumab)	Multiple FDA-approved
Typical Patient Cost	$0–$35/mo for most insured patients	$0–$35/mo (varies by plan)

Yes. The FDA requires biosimilars to demonstrate there are no clinically meaningful differences in safety, purity, and potency compared to the reference product. Amjevita underwent rigorous clinical studies demonstrating biosimilarity to Humira (adalimumab). Your prescriber can discuss whether Amjevita is appropriate for your specific situation.

Many patients do switch from reference biologics to biosimilars. The decision should be made in consultation with your prescriber. Switching is generally safe for stable patients, but your doctor may want to monitor you during the transition. BiologicHealthPlus can coordinate the prior authorization for Amjevita and ensure a seamless supply transition.

Most commercial insurance plans and Medicare Part D cover Amjevita with prior authorization. In many cases, Amjevita may have a lower tier placement on formularies than Humira (adalimumab), potentially reducing your copay. BiologicHealthPlus verifies your insurance coverage, handles all prior authorization, and enrolls you in the Amgen SupportPlus copay program to minimize your out-of-pocket costs.

Without insurance, Amjevita costs approximately $1200/month at list price — lower than Humira (adalimumab)'s list price. Uninsured or underinsured patients may qualify for patient assistance through Amgen SupportPlus. BiologicHealthPlus will find every available savings option for you at no charge.

📚 Sources & Further Reading

🔗

FDA Biosimilar ApprovalsFDA

🔗

BiosimilarWikipedia

🔗

ACR Biosimilar PositionACR

🔗

Biosimilar DevelopmentNIH/NCBI

🔗

Medicare Biosimilar CoverageCMS

Medical Disclaimer: Educational content reviewed by BiologicHealthPlus Clinical Team. Last reviewed: August 2026.

Medical Disclaimer: This page is for informational purposes only. Amjevita requires a valid prescription. Consult your physician before making any changes to your medication. Last updated: August 2026.